Fig. 5From: Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleedingPatients prescribed pharmacologic therapy have higher ESS, which is reduced with antifibrinolytic therapy over time. (a) Patients not assigned to pharmacologic therapy (n = 101) have significant lower ESS compared to patients assigned to either aminocaproic acid (Amicar, n = 14) or tranexamic acid (TA, n = 11). Values represent median ± 5–95% confidence interval, p-values determined by one-way ANOVA with Sidak post-hoc test. (b) Follow up was obtained on 24 patients with median time of 14.5 months. The minimal important difference in ESS is considered to be − 0.71 as noted by dashed line. All patients had a decrease in ESS over time. Compared to patients not on therapy (n = 8), patients whom took either amicar (n = 12) or tranexamic acid (n = 4) had larger reduction of ESS. Values are represented as median ± 95% CIBack to article page